Collegium Pharmaceutical (NASDAQ:COLL) Shares Pass Above 50 Day Moving Average – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $34.08 and traded as high as $37.11. Collegium Pharmaceutical shares last traded at $36.59, with a volume of 1,618,493 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on COLL. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Stock Up 5.0%

The firm has a market cap of $1.19 billion, a P/E ratio of 17.94 and a beta of 0.74. The firm’s 50-day moving average price is $34.08 and its 200 day moving average price is $39.67. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.49 earnings per share. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the business. Vident Advisory LLC grew its position in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after acquiring an additional 281 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Collegium Pharmaceutical by 4.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares during the period. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 285 shares during the last quarter. Atom Investors LP lifted its stake in Collegium Pharmaceutical by 5.0% in the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 318 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.